Streamlining Medicare Imfinzi Prior Authorization Workflows

Navigating the complexities of Medicare Imfinzi prior authorization is a critical challenge for revenue cycle and prior authorization teams. Klivira provides an automated solution designed to streamline these workflows, ensuring timely access to care.

Imfinzi (durvalumab), a PD-L1 inhibitor, is a high-volume prior authorization target across various payer types, including Medicare. For healthcare organizations, understanding the specific prior authorization requirements for Imfinzi under Original Medicare (Fee-for-Service) and Medicare Advantage plans is essential for efficient revenue cycle management and patient care continuity. Klivira's platform is engineered to address these distinct requirements, reducing administrative burden.

Imfinzi Coverage and Prior Authorization Under Original Medicare (Part B)

Imfinzi, an intravenous immunotherapy drug used in indications such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer, and hepatocellular carcinoma (HCC), is typically covered under Medicare Part B as a medically administered drug. Prior authorization requirements for Part B drugs under Original Medicare are generally limited compared to commercial or Medicare Advantage plans. Where prior authorization is required, submissions are routed through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction.

Key Medicare Administrative Contractors (MACs) Handling Part B Claims

Noridian Healthcare Solutions
National Government Services (NGS)
WPS Government Health Administrators
Palmetto GBA
First Coast Service Options (FCSO)
Novitas Solutions

Imfinzi Prior Authorization in Medicare Advantage (Part B and Part D)

Unlike Original Medicare, Medicare Advantage (MA) plans, operated by private insurers, have expanded prior authorization requirements, including for Part B drugs like Imfinzi. MA plans often incorporate their own formularies, step-therapy protocols, and quantity limits, which can vary significantly by plan. While Imfinzi is primarily a Part B drug, some MA plans may have specific coordination-of-benefits or carve-out rules that impact how Part B vs. Part D benefits are administered, necessitating careful review of plan-specific policies.

Policy Adjudication: National and Local Coverage Determinations

Coverage for Imfinzi under Medicare is guided by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by the respective MACs. These policies outline the medical necessity criteria for drug administration. Klivira's platform incorporates NCD/LCD-aware logic to help ensure prior authorization requests align with current coverage guidelines, facilitating accurate and compliant submissions.

Klivira's Approach to Medicare Imfinzi Prior Authorization

Klivira integrates directly with EMR systems and payer portals to automate the prior authorization process for Imfinzi under Medicare. For Original Medicare, our system routes requests through the appropriate MAC-jurisdiction submission channels. For Medicare Advantage plans, Klivira adapts to the broader PA requirements, including plan-specific formularies and submission protocols. This targeted automation significantly reduces manual effort and accelerates approval times.

Navigating Common Denials and Appeals for Imfinzi

Common reasons for Imfinzi prior authorization denials under Medicare can include insufficient documentation of medical necessity, failure to meet NCD/LCD criteria, or incomplete submission data. Klivira's platform helps mitigate these risks by ensuring comprehensive data capture and adherence to payer-specific rules. In the event of a denial, our system supports efficient appeals management, providing a structured pathway to resubmit with additional information or clarification.

Frequently asked questions

Is prior authorization always required for Imfinzi under Original Medicare?

Prior authorization for Part B drugs like Imfinzi is less common under Original Medicare compared to Medicare Advantage plans. However, specific circumstances or local coverage determinations from your MAC may necessitate a PA. Klivira helps identify and manage these requirements.

How do Medicare Advantage plans handle Imfinzi prior authorization differently?

Medicare Advantage plans typically have more extensive prior authorization requirements for Imfinzi, often including specific formularies, step-therapy protocols, and quantity limits. These vary by plan and require close attention to detail for successful approval.

Which Medicare Administrative Contractors (MACs) are relevant for Imfinzi PAs?

For Original Medicare, the relevant MAC depends on your geographic jurisdiction. Key MACs include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. Klivira's system is designed to route submissions to the correct MAC based on provider location.

What role do NCDs and LCDs play in Imfinzi coverage?

National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) are critical policy documents that outline the medical necessity criteria for Imfinzi coverage. Prior authorization requests must align with these guidelines to be approved, and Klivira incorporates this policy logic.

Can Klivira automate prior authorizations for both Original Medicare and Medicare Advantage plans for Imfinzi?

Yes, Klivira automates Imfinzi prior authorizations for both Original Medicare (via MAC-aware routing) and Medicare Advantage plans (adapting to their broader and plan-specific requirements). Our platform connects with relevant submission channels to streamline the process.